Repurposing Valsartan May Protect Against Pulmonary Hypertension
Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.